NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.

News

  1. L'équipe NeuroCyto dans La Provence
  2. Deux nouveaux arrivants dans l'équipe GlioME

    L'équipe 8 (GlioME) a le plaisir d'accueillir deux étudiants en Master 2, Anaïs Arathni étudiante en Master Biologie Santé et Emmanuel Snacel-Fazy étudiant en Master Neurosciences. Anaïs travaillera avec Aurélie Tchoghandjian sur la caractérisation des cellules immunitaires recrutées sur le site tumoral suite au traitement par mimétiques de Smac. Emmanuel travaillera avec Chiara Bastiancich sur le microenvironnement de la résection tumorale du glioblastome.

  3. A commentary from Christophe Leterrier in the Journal of Cell Biology

    Christophe Leterrier, leader of the NeuroCyto ATIP team, wrote a Spotlight in the Journal of Cell Biology highlighting a nice recent paper from the group of Pei-Lin Cheng in Taiwan. In this article, Lee et al. showed how degradation of the chloride transporter NKCC1 by proteasomes anchored at the AIS have a key role in lowering the intracellular chloride concentration, leading to the perinatal reversal of GABA effect from excitatory to inhibitory.

  4. 2019 Retrospective: D. Figarella-Branger from the GlioME team was involved in 5 reference articles on pediatric brain tumours

    Thanks to her expertise in the diagnosis of central nervous system tumours arising in children and young adults, Dominique Figarella-Branger from the GlioME team (Team 8) was involved last year in 5 articles published in high-impact factor journals (>18). These articles are becoming references in this field:

    - The molecular landscape of ETMR at diagnosis and relapse. Nature. 2019 Dec;576(7786):274-280. PMID: 31802000

    - EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncol. 2019 Dec;20(12):e715-e728.PMID: 31797797

  5. "Alzheimer's disease: a year of hope" (La Marseillaise - January 2020)
  6. New publication of the NeuroCyto team

    First work of 2020 work is out for the NeuroCyto team! A collaboration with Matt Rasband’s lab in Nature Communications. This is a significant paper for the axon initial segment field: Matt’s lab used BioID of key AIS proteins for mapping AIS components. Dozens of new candidates for future studies! We performed super-resolution microscopy of several of the newly identified AIS components. IN particular, we showed that Mical3, a protein linking microtubules and actin, forms clusters along the AIS that are not periodically organized along the actin/spectrin scaffold.

  7. France Culture highlights the recent article from the NeuroCyto team
  8. Just out from the NeuroCyto team: the ultrastructure of actin rings revealed

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

"Alzheimer's disease: a year of hope" (La Marseillaise - January 2020)

Maladie d'Alzheimer : une nouvelle année pleine d'espoir. 

In its week-end edition (january the 4th & 5th 2020), the daily newspaper La Marseillaise devoted its "Provence Terre de Science" page to Alzheimer's disease reserach.

On this occasion François Devred (INP team 9 / PINT platform) answered a few questions on the molecular characterization of this complex protein (to be downloaded by clicking here )

Undefined

New publication of the NeuroCyto team

First work of 2020 work is out for the NeuroCyto team! A collaboration with Matt Rasband’s lab in Nature Communications. This is a significant paper for the axon initial segment field: Matt’s lab used BioID of key AIS proteins for mapping AIS components. Dozens of new candidates for future studies! We performed super-resolution microscopy of several of the newly identified AIS components. IN particular, we showed that Mical3, a protein linking microtubules and actin, forms clusters along the AIS that are not periodically organized along the actin/spectrin scaffold.

Undefined

New publication from the GlioME Team and the national POLA network (dedicated to high grade oligodendroglioma) pointing at CDKN2A homozygous deletion as a strong adverse prognostic factor in diffuse malignant IDH-mutant gliomas.

In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).

We showed that:
- CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.

- Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.

English

Michel KHRESTCHATISKY invited to the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS

Michel KHRESTCHATISKY, Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS and co-founder of VECT-HORUS was invited at the third edition of Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS and hosted by BioFIT on December 10, 2019 (https://www.biofit-event.com/translational-neuroscience).

Undefined

New publication for the Neuro-inflammation and Multiple Sclerosis team (INP team 5) in Cytokine about the immunomonitoring of infliximab biotherapies

In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.

Undefined

Partners